Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling

  • Authors:
    • Hitoshi Zembutsu
    • Yasuyo Suzuki
    • Aya Sasaki
    • Tatsuhiko Tsunoda
    • Minoru Okazaki
    • Masataka Yoshimoto
    • Tadashi Hasegawa
    • Koichi Hirata
    • Yusuke Nakamura
  • View Affiliations

  • Published online on: February 1, 2009     https://doi.org/10.3892/ijo_00000159
  • Pages: 361-370
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neoadjuvant chemotherapy with docetaxel for advanced breast cancer can improve the radicality for a subset of patients, but some patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting responses to docetaxel, we analyzed gene expression profiles of biopsy materials from 29 advanced breast cancers using a cDNA microarray consisting of 36,864 genes or ESTs, after enrichment of cancer cell population by laser microbeam microdissection. Analyzing eight PR (partial response) patients and twelve patients with SD (stable disease) or PD (progressive disease) response, we identified dozens of genes that were expressed differently between the ‘responder (PR)’ and ‘non-responder (SD or PD)’ groups. We further selected the nine ‘predictive’ genes showing the most significant differences and established a numerical prediction scoring system that clearly separated the responder group from the non-responder group. This system accurately predicted the drug responses of all of nine additional test cases that were reserved from the original 29 cases. Moreover, we developed a quantitative PCR-based prediction system that could be feasible for routine clinical use. Our results suggest that the sensitivity of an advanced breast cancer to the neoadjuvant chemotherapy with docetaxel could be predicted by expression patterns in this set of genes.

Related Articles

Journal Cover

February 2009
Volume 34 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zembutsu, H., Suzuki, Y., Sasaki, A., Tsunoda, T., Okazaki, M., Yoshimoto, M. ... Nakamura, Y. (2009). Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. International Journal of Oncology, 34, 361-370. https://doi.org/10.3892/ijo_00000159
MLA
Zembutsu, H., Suzuki, Y., Sasaki, A., Tsunoda, T., Okazaki, M., Yoshimoto, M., Hasegawa, T., Hirata, K., Nakamura, Y."Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling". International Journal of Oncology 34.2 (2009): 361-370.
Chicago
Zembutsu, H., Suzuki, Y., Sasaki, A., Tsunoda, T., Okazaki, M., Yoshimoto, M., Hasegawa, T., Hirata, K., Nakamura, Y."Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling". International Journal of Oncology 34, no. 2 (2009): 361-370. https://doi.org/10.3892/ijo_00000159